Article Text

other Versions

Original Research
Admission neutrophil–lymphocyte ratio predicts 90 day outcome after endovascular stroke therapy
  1. Steven D Brooks1,2,
  2. Chauncey Spears1,3,
  3. Christopher Cummings1,4,
  4. Reyna L VanGilder1,3,7,
  5. Kyle R Stinehart1,
  6. Laurie Gutmann1,4,
  7. Jennifer Domico5,
  8. Stacey Culp3,
  9. Jeffrey Carpenter1,5,
  10. Ansaar Rai1,5,
  11. Taura L Barr1,2,3,6,7
  1. 1West Virginia University (WVU) School of Medicine, Morgantown, West Virginia, USA
  2. 2WVU Center for Neuroscience, Morgantown, West Virginia, USA
  3. 3WVU School of Nursing, Morgantown, West Virginia, USA
  4. 4West Virginia University Hospitals Department of Neurology, West Virginia University Hospitals, Morgantown, West Virginia, USA
  5. 5West Virginia University Hospitals Department of Radiology/Interventional Neuroradiology, West Virginia University Hospital, Morgantown, West Virginia, USA
  6. 6West Virginia University Prevention Research Center, Morgantown, West Virginia, USA
  7. 7West Virginia University Department of Emergency Medicine, Morgantown, West Virginia, USA
  1. Correspondence to Dr T L Barr, WVU Prevention Research Center, One Medical Center Drive, PO Box 9303, Morgantown WV 26506-9303, USA; tlbarr{at}


Objective Immune dysregulation influences outcome following acute ischemic stroke (AIS). Admission white blood cell (WBC) counts are routinely obtained, making the neutrophil–lymphocyte ratio (NLR) a readily available biomarker of the immune response to stroke. This study sought to identify the relationship between NLR and 90 day AIS outcome.

Methods A retrospective analysis was performed on patients who underwent endovascular therapy for AIS at West Virginia University Hospitals, Morgantown, West Virginia. Admission WBC differentials were analyzed as the NLR. Stroke severity was measured by the National Institutes of Health Stroke Scale (NIHSS) score and outcome by the modified Rankin Scale (mRS) score at 90 days. Univariate relationships between NLR, age, NIHSS, and mRS were established by correlation coefficients; the t test was used to compare NLR with recanalization and stroke location (anterior vs posterior). Logistic regression models were developed to identify the ability of NLR to predict mRS when controlling for age, recanalization, and treatment with IV tissue plasminogen activator (tPA).

Results 116 patients were reviewed from 2008 to 2011. Mean age of the sample was 67 years, and 54% were women. Mean baseline NIHSS score was 17 and 90 day mRS score was 4. There was a significant relationship between NLR and mRS (p=0.02) that remained when controlling for age, treatment with IV tPA, and recanalization. NLR ≥5.9 predicted poor outcome and death at 90 days.

Conclusions This study shows that the NLR, a readily available biomarker, may be a clinically useful tool for risk stratification when evaluating AIS patients as candidates for endovascular therapies.

  • Inflammatory Response
  • Stroke

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.